

# Yutaro Nakamura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2395682/publications.pdf>

Version: 2024-02-01

158  
papers

3,306  
citations

147566

31  
h-index

223531

46  
g-index

169  
all docs

169  
docs citations

169  
times ranked

3496  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sarcoid-like Granulomatous Lung Disease with Subacute Progression in Silicosis. <i>Internal Medicine</i> , 2022, 61, 395-400.	0.3	3
2	Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 203-217.	2.0	16
3	Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias. <i>Thorax</i> , 2022, 77, 143-153.	2.7	9
4	Association of the Geriatric Nutritional Risk Index With the Survival of Patients With Non-“Small Cell Lung Cancer After Nivolumab Therapy. <i>Journal of Immunotherapy</i> , 2022, 45, 125-131.	1.2	17
5	Involvement of autophagy in exacerbation of eosinophilic airway inflammation in a murine model of obese asthma. <i>Autophagy</i> , 2022, 18, 2216-2228.	4.3	19
6	Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100263.	0.6	3
7	EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100264.	0.6	1
8	Trimethoprim-sulfamethoxazole induced eosinophilic pneumonia: A case report. <i>Respiratory Medicine Case Reports</i> , 2022, 37, 101632.	0.2	1
9	Multiple organ infarction caused by aortic thrombus in a lung cancer patient with the BRAF mutation. <i>Respiratory Medicine Case Reports</i> , 2022, 36, 101608.	0.2	1
10	Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model. <i>Respiratory Research</i> , 2022, 23, 57.	1.4	18
11	Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis. <i>Thorax</i> , 2022, 77, 727-730.	2.7	9
12	Impact of end-of-life respiratory modalities on quality of dying and death and symptom relief in patients with interstitial lung disease: a multicenter descriptive cross-sectional study. <i>Respiratory Research</i> , 2022, 23, 79.	1.4	2
13	Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium. <i>BMC Pulmonary Medicine</i> , 2022, 22, 186.	0.8	3
14	Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211083.	1.1	2
15	Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated <sc>ILD</sc>: A randomized, open-label trial. <i>Respirology</i> , 2021, 26, 370-377.	1.3	24
16	Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis. <i>Clinical Respiratory Journal</i> , 2021, 15, 336-344.	0.6	15
17	Quality of dying and death in patients with interstitial lung disease compared with lung cancer: an observational study. <i>Thorax</i> , 2021, 76, 248-255.	2.7	11
18	Subcutaneous injection of interferon gamma therapy could be useful for anti-“IFN-γ” autoantibody associated disseminated nontuberculous mycobacterial infection. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 373-378.	0.8	11

#	ARTICLE	IF	CITATIONS
19	Erlotinib and bevacizumab in elderly patients ≥75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations. <i>Investigational New Drugs</i> , 2021, 39, 210-216.	1.2	4
20	Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving <sc>antifibrotic</sc> therapy. <i>Respirology</i> , 2021, 26, 171-179.	1.3	24
21	Predictors for bronchoalveolar lavage recovery failure in diffuse parenchymal lung disease. <i>Scientific Reports</i> , 2021, 11, 1682.	1.6	5
22	Cluster analysis-based clinical phenotypes of idiopathic interstitial pneumonias: associations with acute exacerbation and overall survival. <i>BMC Pulmonary Medicine</i> , 2021, 21, 63.	0.8	4
23	Conventional type 2 lung dendritic cells are potent inducers of follicular helper T cells in the asthmatic lung. <i>Allergology International</i> , 2021, 70, 351-359.	1.4	13
24	Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis. <i>Lung</i> , 2021, 199, 289-298.	1.4	11
25	Simple method for detecting idiopathic interstitial pneumonias by measuring vertical lung length on chest X-ray. <i>Scientific Reports</i> , 2021, 11, 7669.	1.6	2
26	Prognostic and Clinical Value of Cluster Analysis in Idiopathic Pleuroparenchymal Fibroelastosis Phenotypes. <i>Journal of Clinical Medicine</i> , 2021, 10, 1498.	1.0	11
27	Impact of bronchoalveolar lavage lymphocytosis on the effects of anti-inflammatory therapy in idiopathic non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and unclassifiable idiopathic interstitial pneumonia. <i>Respiratory Research</i> , 2021, 22, 115.	1.4	5
28	Prognostic classification in acute exacerbation of idiopathic pulmonary fibrosis: a multicentre retrospective cohort study. <i>Scientific Reports</i> , 2021, 11, 9120.	1.6	9
29	Prognostic significance of peripheral blood monocyte and neutrophil counts in rheumatoid arthritis-associated interstitial lung disease. <i>Respiratory Medicine</i> , 2021, 182, 106420.	1.3	12
30	Serum S100A8 and S100A9 as prognostic biomarkers in acute exacerbation of idiopathic pulmonary fibrosis. <i>Respiratory Investigation</i> , 2021, 59, 827-836.	0.9	13
31	Clinical Significance of Interstitial Lung Disease and Its Acute Exacerbation in Microscopic Polyangiitis. <i>Chest</i> , 2021, 159, 2334-2345.	0.4	18
32	Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas. <i>Scientific Reports</i> , 2021, 11, 14999.	1.6	5
33	Clinical Significance of Cold-Inducible RNA-Binding Protein in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2021, 160, 2149-2157.	0.4	7
34	Diagnostic and prognostic significance of serum angiotensin-converting enzyme-1 and -2 concentrations in patients with pulmonary hypertension. <i>Scientific Reports</i> , 2021, 11, 15502.	1.6	4
35	Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 221.	0.8	15
36	Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis. <i>Scientific Reports</i> , 2021, 11, 18579.	1.6	4

#	ARTICLE	IF	CITATIONS
37	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. <i>Respiratory Investigation</i> , 2021, 59, 709-740.	0.9	45
38	Pneumothorax in Patients with Idiopathic Pleuroparenchymal Fibroelastosis: Incidence, Clinical Features, and Risk Factors. <i>Respiration</i> , 2021, 100, 19-26.	1.2	16
39	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. <i>BMC Pulmonary Medicine</i> , 2021, 21, 309.	0.8	2
40	Transient leukocytopenia following combination therapy for COVID-19. <i>Respiratory Investigation</i> , 2021, 60, 158-158.	0.9	3
41	MET Amplification and Efficacy of Nivolumab in Patients With NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100239.	0.6	4
42	Radiological pleuroparenchymal fibroelastosis-like lesion in idiopathic interstitial pneumonias. <i>Respiratory Research</i> , 2021, 22, 290.	1.4	11
43	Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100493.	0.7	1
44	Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy. <i>BMC Pulmonary Medicine</i> , 2021, 21, 409.	0.8	9
45	Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis. <i>Respirology</i> , 2020, 25, 743-749.	1.3	22
46	Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Should Be Treated with Low-dose Prednisolone During Pembrolizumab Therapy: The Authors' Reply. <i>Internal Medicine</i> , 2020, 59, 599-599.	0.3	0
47	Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662095378.	1.0	3
48	Disease course and prognosis of pleuroparenchymal fibroelastosis compared with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2020, 171, 106078.	1.3	23
49	Palliative Care for Idiopathic Pulmonary Fibrosis Patients: Pulmonary Physicians' View. <i>Journal of Pain and Symptom Management</i> , 2020, 60, 933-940.	0.6	20
50	Development of a novel T cell-oriented vaccine using CTL/Th hybrid epitope long peptide and biodegradable microparticles, against an intracellular bacterium. <i>Microbiology and Immunology</i> , 2020, 64, 666-678.	0.7	1
51	Influenza A virus enhances ciliary activity and mucociliary clearance via TLR3 in airway epithelium. <i>Respiratory Research</i> , 2020, 21, 282.	1.4	14
52	Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e2011818.	2.8	26
53	Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662093577.	1.0	13
54	Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1317-1327.	0.5	46

#	ARTICLE	IF	CITATIONS
55	Pneumothorax in connective tissue disease-associated interstitial lung disease. <i>PLoS ONE</i> , 2020, 15, e0235624.	1.1	14
56	Clinical Outcomes of Anti-programmed Death-1 Antibody-Related Pneumonitis in Patients with Non-Small Cell Lung Cancer. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 570-578.	0.3	8
57	Pulse oximetric saturation to fraction of inspired oxygen (SpO <sub>2</sub> /FIO <sub>2</sub> ) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662090632.	1.0	5
58	CD248 and integrin alpha-8 are candidate markers for differentiating lung fibroblast subtypes. <i>BMC Pulmonary Medicine</i> , 2020, 20, 21.	0.8	23
59	Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 143, 47-54.	0.9	6
60	Body composition changes successfully classify prognosis in patients with mycobacterium avium complex lung disease. <i>Journal of Infection</i> , 2019, 79, 341-348.	1.7	9
61	Simultaneous Occurrence of Sarcoidosis and Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis in a Patient with Lung Cancer. <i>Internal Medicine</i> , 2019, 58, 3299-3304.	0.3	8
62	Clinical features of three-dimensional computed tomography-based radiologic phenotypes of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2019, Volume 14, 1333-1342.	0.9	4
63	Analysis of serum adiponectin and leptin in patients with acute exacerbation of idiopathic pulmonary fibrosis. <i>Scientific Reports</i> , 2019, 9, 10484.	1.6	20
64	Clinical significance of lower-lobe interstitial lung disease on high-resolution computed tomography in patients with idiopathic pleuroparenchymal fibroelastosis. <i>Respiratory Medicine</i> , 2019, 154, 122-126.	1.3	20
65	Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases. <i>Respiratory Medicine</i> , 2019, 159, 105811.	1.3	22
66	Effect of rifampicin and clarithromycin on the CYP3A activity in patients with Mycobacterium avium complex. <i>Journal of Thoracic Disease</i> , 2019, 11, 3814-3821.	0.6	8
67	Synchronous Occurrence of Bazex Syndrome and Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in a Patient with Lung Cancer. <i>Internal Medicine</i> , 2019, 58, 3267-3271.	0.3	5
68	Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD. <i>International Journal of COPD</i> , 2019, Volume 14, 1867-1877.	0.9	12
69	Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial. <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 253-261.	1.5	7
70	Prognostic impact of an early marginal decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone. <i>Respiratory Investigation</i> , 2019, 57, 552-560.	0.9	7
71	Correlation of the modified Medical Research Council dyspnea scale with airway structure assessed by three-dimensional CT in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2019, 146, 76-80.	1.3	8
72	Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis. <i>Journal of Rheumatology</i> , 2019, 46, 509-517.	1.0	18

#	ARTICLE	IF	CITATIONS
73	Physiological and morphological differences of airways between COPD and asthmaâ€œCOPD overlap. <i>Scientific Reports</i> , 2019, 9, 7818.	1.6	27
74	Frequency and clinical relevance of anti-cyclic citrullinated peptide antibody in idiopathic interstitial pneumonias. <i>Respiratory Medicine</i> , 2019, 154, 102-108.	1.3	11
75	Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD. <i>Rheumatology</i> , 2019, 58, 2143-2152.	0.9	56
76	Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 147-153.	1.1	17
77	Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibodyâ€œpositive Dermatomyositis-associated Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2019, 46, 935-942.	1.0	28
78	Sarcoidâ€œlike reaction and vitiligo occurring after nivolumab therapy in a patient with metastatic melanoma. <i>Journal of Dermatology</i> , 2019, 46, e359-e360.	0.6	10
79	Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. <i>European Respiratory Journal</i> , 2019, 53, 1802243.	3.1	56
80	Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 531-537.	1.2	3
81	Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity scoreâ€œmatched analysis. <i>Respirology</i> , 2019, 24, 792-798.	1.3	25
82	Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia. <i>Scientific Reports</i> , 2019, 9, 18750.	1.6	28
83	Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis. <i>Chronic Respiratory Disease</i> , 2019, 16, 147997231880947.	1.0	25
84	Podoplaninâ€œpositive myofibroblasts: a pathological hallmark of pleuroparenchymal fibroelastosis. <i>Histopathology</i> , 2018, 72, 1209-1215.	1.6	12
85	Distinctive characteristics and prognostic significance of interstitial pneumonia with autoimmune features in patients with chronic fibrosing interstitial pneumonia. <i>Respiratory Medicine</i> , 2018, 137, 167-175.	1.3	45
86	Neutrophil gelatinase-associated lipocalin in patients with sarcoidosis. <i>Respiratory Medicine</i> , 2018, 138, S20-S23.	1.3	5
87	Body sizeâ€œadjusted dose analysis of pirfenidone in patients with interstitial pneumonia. <i>Respirology</i> , 2018, 23, 318-324.	1.3	27
88	The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis. <i>Respirology</i> , 2018, 23, 519-525.	1.3	35
89	Distinct profile and prognostic impact of body composition changes in idiopathic pulmonary fibrosis and idiopathic pleuroparenchymal fibroelastosis. <i>Scientific Reports</i> , 2018, 8, 14074.	1.6	66
90	IgG4-related disease presenting with combined pulmonary fibrosis and emphysema (CPFE). <i>Respiratory Medicine Case Reports</i> , 2018, 25, 257-260.	0.2	4

#	ARTICLE	IF	CITATIONS
91	IL-17A Attenuates IFN- $\gamma$ Expression by Inducing Suppressor of Cytokine Signaling Expression in Airway Epithelium. <i>Journal of Immunology</i> , 2018, 201, 2392-2402.	0.4	25
92	Macrophage mannose receptor, CD206, predict prognosis in patients with pulmonary tuberculosis. <i>Scientific Reports</i> , 2018, 8, 13129.	1.6	50
93	Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis. <i>Medical Oncology</i> , 2018, 35, 139.	1.2	6
94	Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2018, 12, 117954841877170.	0.5	0
95	Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias. <i>PLoS ONE</i> , 2018, 13, e0199659.	1.1	47
96	Pleuroparenchymal fibroelastosis diagnosed by multidisciplinary discussions in Japan. <i>Respiratory Medicine</i> , 2018, 141, 190-197.	1.3	53
97	Changes in pulmonary endothelial cell properties during bleomycin-induced pulmonary fibrosis. <i>Respiratory Research</i> , 2018, 19, 127.	1.4	30
98	LTBP2 is secreted from lung myofibroblasts and is a potential biomarker for idiopathic pulmonary fibrosis. <i>Clinical Science</i> , 2018, 132, 1565-1580.	1.8	37
99	An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases. <i>Internal Medicine</i> , 2018, 57, 3423-3427.	0.3	3
100	Differences in airway structural changes assessed by 3-dimensional computed tomography in asthma and asthma-chronic obstructive pulmonary disease overlap. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 704-710.e1.	0.5	10
101	Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis. <i>Clinical Respiratory Journal</i> , 2018, 12, 2378-2389.	0.6	31
102	Utility of serum Aspergillus-galactomannan antigen to evaluate the risk of severe acute exacerbation in chronic obstructive pulmonary disease. <i>PLoS ONE</i> , 2018, 13, e0198479.	1.1	7
103	Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study. <i>Medical Oncology</i> , 2018, 35, 108.	1.2	3
104	Evaluation of urinary desmosines as a noninvasive diagnostic biomarker in patients with idiopathic pleuroparenchymal fibroelastosis (PPFE). <i>Respiratory Medicine</i> , 2017, 123, 63-70.	1.3	17
105	Japanese herbal medicine-induced pneumonitis: A review of 73 patients. <i>Respiratory Investigation</i> , 2017, 55, 138-144.	0.9	35
106	Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases. <i>Respiratory Investigation</i> , 2017, 55, 130-137.	0.9	37
107	Respiratory impedance is correlated with morphological changes in the lungs on three-dimensional CT in patients with COPD. <i>Scientific Reports</i> , 2017, 7, 41709.	1.6	30
108	Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy. <i>Respiratory Medicine Case Reports</i> , 2017, 20, 160-163.	0.2	14



#	ARTICLE	IF	CITATIONS
109	Persistent impairment on spirometry in chronic eosinophilic pneumonia. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 422-428.e2.	0.5	16
110	Relationship between fraction of exhaled nitric oxide and airway morphology assessed by three-dimensional CT analysis in asthma. <i>Scientific Reports</i> , 2017, 7, 10187.	1.6	25
111	Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2017, 44, 1394-1401.	1.0	37
112	Clinical diagnosis of idiopathic pleuroparenchymal fibroelastosis: A retrospective multicenter study. <i>Respiratory Medicine</i> , 2017, 133, 1-5.	1.3	89
113	Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. <i>Arthritis Research and Therapy</i> , 2017, 19, 9.	1.6	46
114	Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine. <i>Internal Medicine</i> , 2017, 56, 2367-2371.	0.3	3
115	Non-smoking Chronic Obstructive Pulmonary Disease Attributed to Occupational Exposure to Silica Dust. <i>Internal Medicine</i> , 2017, 56, 1701-1704.	0.3	4
116	Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. <i>PLoS ONE</i> , 2017, 12, e0180283.	1.1	60
117	Pirfenidone for primary Sjögren's syndrome-related fibrotic interstitial pneumonia. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 91-96.	0.2	2
118	Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1011-1018.	1.1	2
119	Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy. <i>Medical Oncology</i> , 2016, 33, 65.	1.2	1
120	Increased levels of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2016, 115, 46-52.	1.3	26
121	Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer. <i>Lung Cancer</i> , 2016, 96, 63-67.	0.9	44
122	Nonspecific interstitial pneumonia preceding diagnosis of collagen vascular disease. <i>Respiratory Medicine</i> , 2016, 117, 40-47.	1.3	32
123	Step-down treatment from medium-dosage of budesonide/formoterol in controlled asthma. <i>Respiratory Medicine</i> , 2016, 119, 1-6.	1.3	14
124	Soluble hemoglobin scavenger receptor CD163 (sCD163) predicts mortality of community-acquired pneumonia. <i>Journal of Infection</i> , 2016, 73, 375-377.	1.7	5
125	Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. <i>Respiratory Medicine</i> , 2016, 121, 91-99.	1.3	121
126	Clinical Significance of Forced Oscillation Technique for Evaluation of Small Airway Disease in Interstitial Lung Diseases. <i>Lung</i> , 2016, 194, 975-983.	1.4	20



#	ARTICLE	IF	CITATIONS
127	Impact of angiopoietin-1 and -2 on clinical course of idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2016, 114, 18-26.	1.3	10
128	Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer. <i>Investigational New Drugs</i> , 2016, 34, 490-496.	1.2	8
129	Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer. <i>European Journal of Cancer</i> , 2016, 58, 30-37.	1.3	29
130	Clinical Implication of Proteinase-3-antineutrophil Cytoplasmic Antibody in Patients with Idiopathic Interstitial Pneumonias. <i>Lung</i> , 2016, 194, 235-242.	1.4	33
131	Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy in non-squamous non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20504-e20504.	0.8	0
132	A case of treatment with voriconazole for chronic progressive pulmonary aspergillosis in a patient receiving tacrolimus for dermatomyositis-associated interstitial lung disease. <i>Respiratory Medicine Case Reports</i> , 2015, 16, 163-165.	0.2	6
133	Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2015, 90, 410-416.	0.9	27
134	Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2015, 9s1, CCRPM.S39897.	0.5	16
135	Nontypeable <i>Haemophilus influenzae</i> exploits the interaction between protein-E and vitronectin for the adherence and invasion to bronchial epithelial cells. <i>BMC Microbiology</i> , 2015, 15, 263.	1.3	20
136	Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2015, 10, 1139.	0.9	9
137	Prognostic Significance of Anti-Aminoacyl-tRNA Synthetase Antibodies in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease: A Retrospective Case Control Study. <i>PLoS ONE</i> , 2015, 10, e0120313.	1.1	74
138	Cumulative Incidence and Predictors of Progression in Corticosteroid-Naïve Patients with Sarcoidosis. <i>PLoS ONE</i> , 2015, 10, e0143371.	1.1	15
139	Evaluation of antibody levels over 3years after 23-valent pneumococcal polysaccharide vaccination in patients with pulmonary diseases receiving steroids and immunosuppressive agents. <i>Clinical Biochemistry</i> , 2015, 48, 125-129.	0.8	5
140	Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival. <i>BMC Pulmonary Medicine</i> , 2015, 15, 15.	0.8	66
141	A case of spontaneous regression of pulmonary mucosa-associated lymphoid tissue (MALT) type lymphoma with Sjögren's syndrome treated with methotrexate for rheumatoid arthritis. <i>Respiratory Medicine Case Reports</i> , 2015, 15, 4-6.	0.2	3
142	Dendriform pulmonary ossification visualised by scanning acoustic microscope. <i>Thorax</i> , 2015, 70, 512-513.	2.7	2
143	Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia. <i>European Respiratory Journal</i> , 2015, 45, 1624-1631.	3.1	32
144	Management of brain metastasis with magnetic resonance imaging and stereotactic irradiation attenuated benefits of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 589.	1.1	47

#	ARTICLE	IF	CITATIONS
145	Indacaterol and tiotropium combination therapy in patients with chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 30, 11-15.	1.1	6
146	Synergistic Proinflammatory Responses by IL-17A and Toll-Like Receptor 3 in Human Airway Epithelial Cells. <i>PLoS ONE</i> , 2015, 10, e0139491.	1.1	12
147	Plasma connective tissue growth factor levels as potential biomarkers of airway obstruction in patients with asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2014, 113, 295-300.	0.5	10
148	Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. <i>Lung Cancer</i> , 2014, 84, 259-264.	0.9	56
149	Usual Interstitial Pneumonia Preceding Collagen Vascular Disease: A Retrospective Case Control Study of Patients Initially Diagnosed with Idiopathic Pulmonary Fibrosis. <i>PLoS ONE</i> , 2014, 9, e94775.	1.1	61
150	Prognostic Factors for Myositis-Associated Interstitial Lung Disease. <i>PLoS ONE</i> , 2014, 9, e98824.	1.1	131
151	Retrospective evaluation of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer with stereotactic radiotherapy: A multi-institutional study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7591-7591.	0.8	1
152	Multidetector-row computed tomography assessment of adding budesonide/formoterol to tiotropium in patients with chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 336-341.	1.1	13
153	Rheumatoid lung disease: Prognostic analysis of 54 biopsy-proven cases. <i>Respiratory Medicine</i> , 2012, 106, 1164-1169.	1.3	72
154	Idiopathic pleuroparenchymal fibroelastosis: consideration of a clinicopathological entity in a series of Japanese patients. <i>BMC Pulmonary Medicine</i> , 2012, 12, 72.	0.8	81
155	Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD). <i>Respiratory Medicine</i> , 2010, 104, 1527-1534.	1.3	52
156	Quantitative Analysis of Fibroblastic Foci in Usual Interstitial Pneumonia. <i>Chest</i> , 2006, 130, 22-29.	0.4	87
157	Induction of Protective Immunity to <i>Listeria monocytogenes</i> with Dendritic Cells Retrovirally Transduced with a Cytotoxic T Lymphocyte Epitope Minigene. <i>Infection and Immunity</i> , 2003, 71, 1748-1754.	1.0	17
158	Nonspecific interstitial pneumonia in collagen vascular diseases: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2003, 20, 235-41.	0.2	46